These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28594344)

  • 1. Design and Synthesis of Non-Peptide Mimetics Mapping the Immunodominant Myelin Basic Protein (MBP
    Yannakakis MP; Simal C; Tzoupis H; Rodi M; Dargahi N; Prakash M; Mouzaki A; Platts JA; Apostolopoulos V; Tselios TV
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics at the receptor level of immunodominant myelin oligodendrocyte glycoprotein 35-55 epitope implicated in multiple sclerosis.
    Yannakakis MP; Tzoupis H; Michailidou E; Mantzourani E; Simal C; Tselios T
    J Mol Graph Model; 2016 Jul; 68():78-86. PubMed ID: 27388119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis.
    Hong J; Zang YC; Tejada-Simon MV; Kozovska M; Li S; Singh RA; Yang D; Rivera VM; Killian JK; Zhang JZ
    J Immunol; 1999 Sep; 163(6):3530-8. PubMed ID: 10477628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response.
    Mantzourani ED; Platts JA; Brancale A; Mavromoustakos TM; Tselios TV
    J Mol Graph Model; 2007 Sep; 26(2):471-81. PubMed ID: 17392002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G; Rodi M; Kalbacher H; Chatzantoni K; Karagiannis F; Synodinos L; Plotas P; Papalois A; Dimisianos N; Papathanasopoulos P; Gatos D; Tselios T; Apostolopoulos V; Mouzaki A; Matsoukas J
    Eur J Med Chem; 2015 Aug; 101():13-23. PubMed ID: 26112377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications.
    Kozovska M; Zang YC; Aebischer I; Lnu S; Rivera VM; Crowe PD; Boehme SA; Zhang JZ
    Eur J Immunol; 1998 Jun; 28(6):1894-901. PubMed ID: 9645371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.
    Karin N; Mitchell DJ; Brocke S; Ling N; Steinman L
    J Exp Med; 1994 Dec; 180(6):2227-37. PubMed ID: 7525850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au.
    He XL; Radu C; Sidney J; Sette A; Ward ES; Garcia KC
    Immunity; 2002 Jul; 17(1):83-94. PubMed ID: 12150894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP
    Tapeinou A; Giannopoulou E; Simal C; Hansen BE; Kalofonos H; Apostolopoulos V; Vlamis-Gardikas A; Tselios T
    Eur J Med Chem; 2018 Jan; 143():621-631. PubMed ID: 29216561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational analysis of the ΜΒΡ83-99 (Phe91) and ΜΒΡ83-99 (Tyr91) peptide analogues and study of their interactions with the HLA-DR2 and human TCR receptors by using molecular dynamics.
    Potamitis C; Matsoukas MT; Tselios T; Mavromoustakos T; Golič Grdadolnik S
    J Comput Aided Mol Des; 2011 Sep; 25(9):837-53. PubMed ID: 21898163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.
    Fridkis-Hareli M; Santambrogio L; Stern JN; Fugger L; Brosnan C; Strominger JL
    J Clin Invest; 2002 Jun; 109(12):1635-43. PubMed ID: 12070311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.
    Aharoni R; Teitelbaum D; Arnon R; Sela M
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):634-9. PubMed ID: 9892685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 3A6-TCR/superagonist/HLA-DR2a complex shows similar interface and reduced flexibility compared to the complex with self-peptide.
    Salutari I; Martin R; Caflisch A
    Proteins; 2020 Jan; 88(1):31-46. PubMed ID: 31237711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.
    Muraro PA; Vergelli M; Kalbus M; Banks DE; Nagle JW; Tranquill LR; Nepom GT; Biddison WE; McFarland HF; Martin R
    J Clin Invest; 1997 Jul; 100(2):339-49. PubMed ID: 9218510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential signaling and hierarchical response thresholds induced by an immunodominant peptide of myelin basic protein and an altered peptide ligand in human T cells.
    Crowe PD; Boehme SA; Wong T; Gaur A; Sidney J; Sette A; Conlon PJ
    Hum Immunol; 1998 Nov; 59(11):679-89. PubMed ID: 9796736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein.
    Liu J; Wu P; Gao F; Qi J; Kawana-Tachikawa A; Xie J; Vavricka CJ; Iwamoto A; Li T; Gao GF
    J Virol; 2010 Nov; 84(22):11849-57. PubMed ID: 20844028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides.
    Tselios T; Daliani I; Probert L; Deraos S; Matsoukas E; Roy S; Pires J; Moore G; Matsoukas J
    Bioorg Med Chem; 2000 Aug; 8(8):1903-9. PubMed ID: 11003134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positioning of autoimmune TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex.
    Kato Z; Stern JN; Nakamura HK; Kuwata K; Kondo N; Strominger JL
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15523-8. PubMed ID: 18824684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
    Matsoukas J; Apostolopoulos V; Kalbacher H; Papini AM; Tselios T; Chatzantoni K; Biagioli T; Lolli F; Deraos S; Papathanassopoulos P; Troganis A; Mantzourani E; Mavromoustakos T; Mouzaki A
    J Med Chem; 2005 Mar; 48(5):1470-80. PubMed ID: 15743189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation.
    Tselios T; Apostolopoulos V; Daliani I; Deraos S; Grdadolnik S; Mavromoustakos T; Melachrinou M; Thymianou S; Probert L; Mouzaki A; Matsoukas J
    J Med Chem; 2002 Jan; 45(2):275-83. PubMed ID: 11784132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.